Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa-Part A: A Randomized Trial of Ring Vaccination to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. Part B- Safety and immunogenicity of VSV¿G/ZEBOV-GP among Frontline Workers

Trial Profile

A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa-Part A: A Randomized Trial of Ring Vaccination to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. Part B- Safety and immunogenicity of VSV¿G/ZEBOV-GP among Frontline Workers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 05 Oct 2022 Results of post-hoc pooled analysis of 3 studies(PREVAIL:NCT02344407; FLW: PACTR201503001057193; STRIVE:NCT02378753) published in the Vaccine
    • 25 Oct 2020 Results of post-hoc pooled analysis of 3 studies (Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL)), presented at the IDWeek 2020.
    • 19 Dec 2019 According to a Food and Drug Administration media release, the Food and Drug Administration (FDA) has approved Ervebo, a vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older.The approval of Ervebo is supported by this study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top